[go: up one dir, main page]

AR109279A1 - Anticuerpos anti plazomicina y métodos de uso de los mismos - Google Patents

Anticuerpos anti plazomicina y métodos de uso de los mismos

Info

Publication number
AR109279A1
AR109279A1 ARP170102193A ARP170102193A AR109279A1 AR 109279 A1 AR109279 A1 AR 109279A1 AR P170102193 A ARP170102193 A AR P170102193A AR P170102193 A ARP170102193 A AR P170102193A AR 109279 A1 AR109279 A1 AR 109279A1
Authority
AR
Argentina
Prior art keywords
plazomycin
antibodies
methods
same
levels
Prior art date
Application number
ARP170102193A
Other languages
English (en)
Inventor
Shuang Wu
Jr Richard Theolis
Christopher E Henry
Kristina Oresic Bender
Original Assignee
Achaogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Achaogen Inc filed Critical Achaogen Inc
Publication of AR109279A1 publication Critical patent/AR109279A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Anticuerpos antiplazomicina y métodos de uso de los mismos, por ejemplo, en la determinación de los niveles de plazomicina en muestras de pacientes humanos bajo tratamiento con plazomicina. Los anticuerpos son útiles, por ejemplo para monitorear los niveles de plazomicina durante el tratamiento de enfermedades infecciosas.
ARP170102193A 2016-08-03 2017-08-02 Anticuerpos anti plazomicina y métodos de uso de los mismos AR109279A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662370580P 2016-08-03 2016-08-03

Publications (1)

Publication Number Publication Date
AR109279A1 true AR109279A1 (es) 2018-11-14

Family

ID=59582061

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP170102193A AR109279A1 (es) 2016-08-03 2017-08-02 Anticuerpos anti plazomicina y métodos de uso de los mismos

Country Status (5)

Country Link
US (1) US20190352426A1 (es)
EP (1) EP3494143B1 (es)
AR (1) AR109279A1 (es)
TW (1) TWI765900B (es)
WO (1) WO2018026969A2 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2020010094A (es) * 2018-04-06 2021-01-15 Dana Farber Cancer Inst Inc Kir3dl3 como receptor de hhla2, anticuerpos anti-hhla2 y usos de estos.
CN111814381B (zh) * 2020-07-21 2024-02-06 秦皇岛玻璃工业研究设计院有限公司 玻璃锡槽工作模型及其建立方法
CN116640222B (zh) * 2022-02-16 2024-09-24 东莞市朋志生物科技有限公司 抗2,4-二硝基苯酚的抗体、包含其的偶联物、试剂、试剂盒及其应用
CN116925218B (zh) * 2023-09-19 2023-12-05 北京索莱宝科技有限公司 小热休克蛋白hspb1的抗体、抗体组合物、杂交瘤细胞株及其应用

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4237224A (en) 1974-11-04 1980-12-02 Board Of Trustees Of The Leland Stanford Jr. University Process for producing biologically functional molecular chimeras
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US5955584A (en) * 1986-03-31 1999-09-21 Charter Ventures Atherosclerotic plaque specific antigens, antibodies thereto, and uses thereof
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
CA2026147C (en) 1989-10-25 2006-02-07 Ravi J. Chari Cytotoxic agents comprising maytansinoids and their therapeutic use
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5151510A (en) 1990-04-20 1992-09-29 Applied Biosystems, Inc. Method of synethesizing sulfurized oligonucleotide analogs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US6765087B1 (en) 1992-08-21 2004-07-20 Vrije Universiteit Brussel Immunoglobulins devoid of light chains
DE69329974T2 (de) 1992-12-04 2001-07-19 Medical Research Council, London Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
US5293050A (en) 1993-03-25 1994-03-08 International Business Machines Corporation Semiconductor quantum dot light emitting/detecting devices
WO1994025591A1 (en) 1993-04-29 1994-11-10 Unilever N.V. PRODUCTION OF ANTIBODIES OR (FUNCTIONALIZED) FRAGMENTS THEREOF DERIVED FROM HEAVY CHAIN IMMUNOGLOBULINS OF $i(CAMELIDAE)
US5837458A (en) 1994-02-17 1998-11-17 Maxygen, Inc. Methods and compositions for cellular and metabolic engineering
US5675063A (en) 1995-02-28 1997-10-07 Loyola University Of Chicago Immortalized rabbit hybridoma fusion partner
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
WO1999029888A1 (en) 1997-12-05 1999-06-17 The Scripps Research Institute Humanization of murine antibody
DK1522590T3 (da) 2000-06-28 2009-12-21 Glycofi Inc Fremgangsmåde til fremstilling af modificerede glykoproteiner
US6653456B2 (en) * 2001-07-31 2003-11-25 Roche Diagnostics Corporation Site-specific aminoglycoside derivatives and their use in immunodiagnostic assays
US7462697B2 (en) 2004-11-08 2008-12-09 Epitomics, Inc. Methods for antibody engineering
CA2595682A1 (en) 2005-01-31 2006-08-03 Ablynx N.V. Method for generating variable domain sequences of heavy chain antibodies
US7429487B2 (en) 2005-07-05 2008-09-30 Epitomics, Inc. Fusion partner for production of monoclonal rabbit antibodies
KR20080090406A (ko) 2005-11-28 2008-10-08 젠맵 에이/에스 재조합 １가 항체 및 그의 제조 방법
AU2009296937B2 (en) * 2008-09-29 2015-02-12 Centocor Ortho Biotech Inc. Anti-CD147 antibodies, methods, and uses
US9209965B2 (en) 2014-01-14 2015-12-08 Microsemi Semiconductor Ulc Network interface with clock recovery module on line card
BR112016018891A2 (pt) * 2014-02-21 2017-10-10 Abbvie Stemcentrx Llc anticorpos anti-dll3 e conjugados de fármacos para uso em melanoma

Also Published As

Publication number Publication date
EP3494143A2 (en) 2019-06-12
US20190352426A1 (en) 2019-11-21
TWI765900B (zh) 2022-06-01
TW201815826A (zh) 2018-05-01
WO2018026969A3 (en) 2018-03-15
EP3494143B1 (en) 2022-10-05
WO2018026969A2 (en) 2018-02-08

Similar Documents

Publication Publication Date Title
CY1124293T1 (el) Αγωνιστης υποδοχεα γλυκοκορτικοειδων και ανοσοσυζευγματα αυτου
JOP20200192A1 (ar) أجسام مضادة لـ tigit
CL2017000651A1 (es) Anticuerpos anti-glucagón y sus usos
CR20160270A (es) ANTICUERPOS ANTI-TAU (pS422) HUMANIZADOS Y MÉTODOS DE UTILIZACIÓN
CL2018001587A1 (es) Anticuerpos neutralizadores del virus de inmunodeficiencia humana
GEAP202315361A (en) Antibodies against signal-regulatory protein alpha and methods of use
MX2016005631A (es) Anticuerpos anti-alfa-sinucleina y metodos de uso.
MX390014B (es) Compuestos de dinucleótidos cíclicos y métodos de uso.
MX2017005920A (es) Anticuerpos anti-tim3 y metodos de uso.
MX2017000116A (es) Moleculas basadas en il-15 y metodos para su uso.
CO2017005784A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
CO2017007121A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
MX2018001532A (es) Anticuerpos anti-angptl8 y usos de estos.
EA201890725A1 (ru) Агонисты фарнезоидного х-рецептора и их применение
MX386587B (es) ANTICUERPOS ANTI-CD79b Y MÉTODOS DE USO.
MX372675B (es) Anticuerpos anti-jagged1 y metodos de uso.
CY1125938T1 (el) Θεραπεια με βλαστοκυτταρα σε παθολογιες του ενδομητριου
CL2015002835A1 (es) Nuevos derivados de piridina
CL2015003174A1 (es) Anticuerpos anti-igf-1r con abolición de la unión al fcrn y su utilización en el tratamiento de enfermedades oculares vasculares
MX2022002954A (es) Anticuerpos anti-htra1 y metodos de uso de los mismos.
MX2018013409A (es) Métodos y dispositivos para la preparación de agentes de contraste de ultrasonido.
AR109279A1 (es) Anticuerpos anti plazomicina y métodos de uso de los mismos
MX395376B (es) Dispositivo para la deteccion de proteinas mal plegadas y metodos de uso del mismo.
MX2017006075A (es) Biomarcadores para la progresion de enfermedades en melanoma.
MX2016015280A (es) Anticuerpos anti-bromodesoxiuridina(brdu) y metodos de uso.

Legal Events

Date Code Title Description
FB Suspension of granting procedure